Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Brian Godman, Mainul Haque, Santosh Kumar, Salequl Islam, Jaykaran Charan, Farhana Akter, Amanj Kurdi, Eleonora Allocati, Muhammed Abu Bakar, Sagir Abdur Rahim, Nusrat Sultana, Farzana Deeba, M. A. Halim Khan, A. B. M Muksudul Alam, Iffat Jahan, Zubair Mahmood Kamal, Humaira Hasin, Munzur-E-Murshid, Shamsun Nahar, Monami Haque, Siddhartha Dutta, Jha Pallavi Abhayanand, Rimple Jeet Kaur, Jitendra Acharya, Takuma Sugahara, Hye-Young Kwon, SeungJin Bae, Karen Koh Pek Khuan, Tanveer Ahmed Khan, Shahzad Hussain, Zikria Saleem, Alice Pisana, Janney Wale & Mihajlo Jakovljevic. (2021) Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future. Current Medical Research and Opinion 37:9, pages 1529-1545.
Read now
Read now
Johan Jendle, Åsa Ericsson, Bertil Ekman, Stefan Sjöberg, Jens Gundgaard, João da Rocha Fernandes, Ann-Charlotte Mårdby, Barnaby Hunt, Samuel J. P. Malkin & Maria Thunander. (2020) Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective. Journal of Medical Economics 23:11, pages 1311-1320.
Read now
Read now
Edurne Lecumberri, Maite Ortega, Marta Iturregui, José Antonio Quesada, Clotilde Vázquez & Domingo Orozco. (2018) Quality-of-life and treatment satisfaction in actual clinical practice of patients with Type 1 diabetes mellitus (T1DM) and hypoglycemia treated with insulin degludec. Current Medical Research and Opinion 34:6, pages 1053-1059.
Read now
Read now
Articles from other publishers (13)
Abdulhamid Althagafi, Mohannad Alshibani, Samah O Alshehri, Afnan Barahim, Haneen Alghamdi, Dania Alaslani, Aisha Qari, Abdulaziz Almulhim & Ahmad Alamer. (2022) The Clinical Impact of Switching Basal Insulin to Insulin Degludec in Patients With Diabetes in Saudi Arabia: A Retrospective One-Group Pretest-Posttest Design Study. Cureus.
Crossref
Crossref
Hailey Saunders, Ba’ Pham, Desmond Loong, Sujata Mishra, Huda M. Ashoor, Jesmin Antony, Nazia Darvesh, Silkan K. Bains, Margaret Jamieson, Donna Plett, Srushhti Trivedi, Catherine H. Yu, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review. Value in Health 25:7, pages 1235-1252.
Crossref
Crossref
J. Pöhlmann, K. Norrbacka, K. S. Boye, W. J. Valentine & H. Sapin. (2020) Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy. The European Journal of Health Economics 21:8, pages 1179-1196.
Crossref
Crossref
Alice Cheng, Timothy S. Bailey, Didac Mauricio & Ronan Roussel. (2020)
Insulin glargine 300 U/
mL
and insulin degludec: A review of the current evidence comparing these two second‐generation basal insulin analogues
. Diabetes/Metabolism Research and Reviews 36:7.
Crossref
Crossref
Richard F. Pollock, William J. Valentine, Steven P. Marso, Andreas Andersen, Jens Gundgaard, Nino Hallén, Deniz Tutkunkardas, Elizabeth A. Magnuson & John B. Buse. (2019) Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Applied Health Economics and Health Policy 17:5, pages 615-627.
Crossref
Crossref
Wen Su, Chaoyun Li, Lei Zhang, Ziyi Lin, Jun Tan & Jianwei Xuan. (2019) Meta-Analysis and Cost-Effectiveness Analysis
of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2
Diabetes in China. Diabetes Therapy 10:5, pages 1969-1984.
Crossref
Crossref
Rebeca Reyes-García, Óscar Moreno-Pérez, Cristina Tejera-Pérez, Diego Fernández-García, Virginia Bellido-Castañeda, Martín López de la Torre Casares, Pedro Rozas-Moreno, José Carlos Fernández-García, Amparo Marco Martínez, Javier Escalada-San Martín, Manuel Gargallo-Fernández, Manuel Botana-López, Judith López-Fernández, José Miguel González-Clemente, Esteban Jódar-Gimeno & Pedro Mezquita-Raya. (2019) Documento de abordaje integral de la diabetes tipo 2. Endocrinología, Diabetes y Nutrición 66:7, pages 443-458.
Crossref
Crossref
Rebeca Reyes-García, Óscar Moreno-Pérez, Cristina Tejera-Pérez, Diego Fernández-García, Virginia Bellido-Castañeda, Martín López de la Torre Casares, Pedro Rozas-Moreno, José Carlos Fernández-García, Amparo Marco Martínez, Javier Escalada-San Martín, Manuel Gargallo-Fernández, Manuel Botana-López, Judith López-Fernández, José Miguel González-Clemente, Esteban Jódar-Gimeno & Pedro Mezquita-Raya. (2019) A comprehensive approach to type 2 diabetes mellitus – A recommendation document. Endocrinología, Diabetes y Nutrición (English ed.) 66:7, pages 443-458.
Crossref
Crossref
Jakob Langer, Michael L. Wolden, Seiya Shimoda, Miki Sato & Eiichi Araki. (2019) Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy. Diabetes Therapy 10:4, pages 1347-1356.
Crossref
Crossref
Richard F. Pollock, Simon Heller, Thomas R. Pieber, Vincent Woo, Jens Gundgaard, Nino Hallén, Maria Luckevich, Deniz Tutkunkardas & Bernard Zinman. (2019) Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes, Obesity and Metabolism 21:7, pages 1706-1714.
Crossref
Crossref
Huafeng Cheng, Xu Wan, Jing Ma & Bin Wu. (2019) Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Insulin-naive Chinese Patients With Type 2 Diabetes. Clinical Therapeutics 41:3, pages 445-455.e4.
Crossref
Crossref
Russell Drummond, Samuel Malkin, Michelle Du Preez, Xin Ying Lee & Barnaby Hunt. (2018) The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. Diabetes, Obesity and Metabolism 20:10, pages 2371-2378.
Crossref
Crossref
Satish K. GargAmanda H. RewersH. Kaan Akturk. (2018) New Medications for the Treatment of Diabetes. Diabetes Technology & Therapeutics 20:S1, pages S-139-S-153.
Crossref
Crossref